CONFIRM: Magnetic Resonance Guided Radiation Therapy

Launched by BRIGHAM AND WOMEN'S HOSPITAL · Apr 28, 2020

Keywords

ClinConnect Summary

The CONFIRM trial is studying a new way to treat certain types of cancer, including gastric cancer and different forms of breast cancer, using a combination of special radiation therapy guided by MRI (which is a type of imaging that creates detailed pictures of the inside of the body) and chemotherapy. The goal is to see how safe and effective this treatment is for patients. The machine used in this study is called the MRIdian Linear Accelerator, which allows doctors to target tumors more precisely while minimizing damage to surrounding healthy tissue.

To participate in this trial, you need to be at least 18 years old and have a confirmed diagnosis of cancer that requires radiation treatment. You should also be able to understand what the study involves and agree to participate by signing a consent form. However, if you have severe anxiety about being in tight spaces (claustrophobia) or if you cannot undergo an MRI for any reason, you may not be eligible. Participants in the trial can expect close monitoring and support throughout the treatment process. This study is currently recruiting participants, and it aims to help improve cancer treatment options in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Participants must have histologically or cytologically confirmed malignancy requiring radiation
• • Age 18 years of older
• • ECOG performance status ≤2 (Karnofsky ≥60%, see Appendix A)
• • Ability to understand and the willingness to sign a written informed consent document.
• • Any further criteria listed in the specific disease site cohort
• • Exclusion Criteria
• • History of allergic reactions attributed to gadolinium-based IV contrast
• • -- Note: If patient will not receive contrast, this is not applicable and kidney function will not affect eligibility
• • Severe claustrophobia or anxiety
• • Participants who cannot undergo an MRI
• • Any other exclusion criteria listed in the specific disease site cohort